Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

Kelpi is tackling plastic pollution by developing sustainable alternatives to single-use plastic packaging. It uses seaweed to create a unique bioplastic coating that provides a world-leading water barrier for new-generation packaging while being recyclable, biodegradable, and low carbon. By working with major food and drink, cosmetics and home care brands, Kelpi is already reducing reliance on fossil-fuel plastics and paving the way for a greener future in these industries.

Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.

Folium Science is increasing agricultural productivity by enhancing animal welfare and feed efficiency in livestock farming while reducing environmental impact. Its unique CRISPR-Cas technology platform harnesses natural biological systems to safely modulate animal microbiomes by regulating metabolic functions and targeting unwanted bacteria with extreme precision. This approach helps reduce reliance on antibiotics and can be applied to both plants and soil to improve their bacterial biomes for optimal growing conditions.